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Previous reports have indicated that benzothio-
phenes exhibit broad anti-inflammatory properties and
inhibit human immunodeficiency virus-type 1 (HIV-1)
replication. We show that the immunosuppressant cy-
closporin A (CsA) and benzothiophene-2-carboxamide,
5-methoxy-3-(1-methyl ethoxy)-1-oxide (PD 144795)
block the induction of p53 and NF-kB binding to the
HIV-1 long terminal repeat (LTR) by the T cell receptor
activator phytohemagglutinin. CsA and PD 144795 also
inhibit the induction by phytohemagglutinin of the
transcription mediated by an HIV-1 LTR fragment con-
taining the p53 and NF-kB sites. These effects of PD
144795 on HIV-1 transcription correlate with its ability
to inhibit the phosphatase activity of calcineurin and
are similar to those previously described for CsA. More-
over, a constitutive active form of calcineurin is able to
induce expression from the HIV-1 LTR in a p53- and
NF-kB-dependent manner and PD 144795 is able to block
this induction. These results demonstrate that the DNA
binding of p53 to the HIV-1 LTR can be modulated by
calcineurin and provide a framework to understand the
anti-HIV properties of benzothiophene derivatives.
Benzothiophene derivatives have been shown to have both
anti-inflammatory and anti-HIV1 effects. Originally, these
compounds were shown to block expression of cellular adhesion
molecules and to exhibit anti-inflammatory properties (1). Re-
cently, benzothiophene derivatives were shown to block HIV-1
transcription in response to tumor necrosis factor a stimulation
of promyelocytes (2). Additionally, these compounds blocked
constitutive HIV-1 transcription in chronically infected cells
and induced a latency state in cytokine-activated cells. The
benzothiophene derivatives did not block the activation of
NF-kB in response to tumor necrosis factor a treatment and did
not block Tat function (2). In this report, we have studied the
effects of PD 144795 (Parke-Davis Pharmaceuticals) (Fig. 1) on
HIV-1 LTR-directed transcription in Jurkat T cells.
The expression of HIV-1 genes is controlled in part by the
interaction of sequence-specific transcription factors with the
LTR region of the provirus. NF-kB, Sp1, and other sequence-
specific transcription factors have been shown to control tran-
scription initiation directed by HIV LTR (3, 4). We have re-
cently identified an inducible form of p53 in Jurkat T cells that
directly interacts with a specific DNA-binding site positioned
immediately downstream to the most 59 Sp1-binding site in the
HIV-1 LTR (5, 6). We have also shown that this DNA element
mediates the induction of the HIV-1 LTR transcriptional activ-
ity by tumor promoting mutant forms of p53 (5). These results
provide a mechanism to explain the dramatic increase in HIV-1
replication observed after the overexpression of mutant p53 in
cells that completely lack expression of this protein (7).
It is well known that the replication of the HIV-1 virus in
lymphocytes correlates with the activation/proliferation status
of the infected cell (8, 9). Treatment of HIV-1-infected Jurkat
cells with T cell receptor (TCR) or protein kinase C activators
induces HIV-1 replication (10, 11). Previous reports have indi-
cated that ligands of the TCR activate LTR-dependent tran-
scription through a CsA-sensitive mechanism (12–14). CsA,
through its interaction with cyclophilin (reviewed in Ref. 15),
acts as an strong inhibitor of the serine/threonine phosphatase
CN (16, 17). This enzyme is a heterotrimeric complex consist-
ing of a 59-kDa catalytic subunit, calcineurin A subunit, a
calcium-binding regulatory subunit of 19 kDa, calcineurin B
subunit, and a 17-kDa calcium-binding protein, calmodulin.
CN plays a critical role in the regulation of calcium-depend-
ent signaling pathways that are necessary for T cell activation
(16, 18, 19). This enzyme regulates the nuclear translocation of
NF-ATp, a transcription factor implicated in the expression of
several cytokines (20). Also, CN inhibitors are known to de-
crease HIV-1 viral replication and to inhibit HIV-1 LTR-medi-
ated transcription (12, 21). Inhibition of NF-kB binding to the
LTR region of the HIV-1 provirus has been suggested as the
mechanism by which CN inhibitors would repress the tran-
scriptional activity mediated by this promoter (14, 22). Intrigu-
ingly, the relatively large number of genes whose expression is
modulated by CN inhibitors in T cells (23, 24) suggests that, in
addition to NF-AT and NF-kB, other transcription factors could
be affected by these drugs.
In this study we have investigated the effect of CsA and PD
144795 on the transcriptional activity mediated by p53 and
NF-kB. Using several approaches we demonstrate that cal-
cineurin is implicated in the regulation of p53 transcriptional
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activity, that PD 144795 is an inhibitor of calcineurin, and that
the DNA binding and transactivation of p53 to the HIV-1 LTR
can be modulated by calcineurin inhibitors. These results offer
insight into the understanding of the molecular basis for the
inflammatory and anti-HIV properties of benzothiophene
derivatives.
EXPERIMENTAL PROCEDURES
PD 144795—Compound PD 144795 (Fig. 1) was synthesized by
Parke-Davis Pharmaceutical Research as described previously (1).
Electrophoretic Mobility Shift Assays—The LTR B sequences were as
described (5). DNA oligonucleotides were prepared with an Applied
Biosystems 391EP DNA synthesizer using the phosphoramidite
method, and purified by Sep-Pak C18 cartridges (Waters Associates).
p53 gel shift mobility assays were prepared as follows: a 10-ml reaction
volume containing the binding reaction buffer (20 mM Hepes pH 7.5,
400 mM NaCl, 5 mM MgCl2, 1 mM ZnCl2, 1 mM b-mercaptoethanol, 0.5
mM phenylmethylsulfonyl fluoride, 5% glycerol) and 1–2 mg of protein
nuclear extract was mixed with 2 mg of poly(dIzdC) and 0.2 ng of
radiolabeled probes and incubated at room temperature for 30 min.
Reactions were loaded onto a 3.8% polyacrylamide gel previously pre-
run for 15 min. The NF-kB HIV-1 EMSA sequence was as follows
(double strand): CGCTGGGGACTTTCCAGGG. NF-kB EMSA reactions
were prepared as described previously (25). The octamer site (under-
lined) was from sequences 260 to 241 of the HLA DRa gene (double
strand): AGTAATTGATTTGCATTTTA (46).
Plasmids, Cell Culture, Cell Extracts, Transfections, and CAT As-
says—The 2121,1232 HIV-1 LTR CAT reporter plasmid construct was
a gift from B. Stein. PG13 and pSRa-DCAM-AI were a gift from B.
Vogelstein and E. A. O’Neill, respectively. NF-kB/p53E1BTATA CAT,
HIV1Dp53CAT, and HIV1DNF-kBCAT have been previously described
(5, 26). Plasmids were prepared with Qiagen columns according to the
directions of the manufacturers.
Jurkat T leukemia cells from ATCC were cultured at 0.1–0.5 3 105
cells/ml in a-minimal essential medium, 2% heat inactivated fetal calf
serum (Irvine), and penicillin/streptomycin. When incubations were
performed, cells were centrifuged, resuspended in new media at 1 3 106
cells/ml, and incubated as indicated. Incubations were stopped by cen-
trifugation and cells were processed for the preparation of nuclear ex-
tracts as described (25) but a final concentration of 1 mM phenylmethyl-
sulfonyl fluoride was used. Extracts were aliquoted and stored at 280 °C.
For transfection experiments, Jurkat or CEM lymphocytes were
transfected by electroporation at 5 3 106 cells, 0.5 ml of phosphate-
buffered saline and resuspended in 10 ml of media. Incubations were
carried out for 24–48 h. Cells were lysed by a 3-s ultrasonic vibration at
4 °C using a Branson Sonifier at setting 3. Equal amounts of protein, as
determined by the Bradford assay (Bio-Rad), were then analyzed for
chloramphenicol acetyltransferase (CAT) activity using the fluor diffu-
sion assay (27).
Calcineurin Phosphatase Assay—Cell extracts were prepared as fol-
lows: 106 Jurkat lymphocytes per experimental condition were washed
in phosphate-buffered saline and lysed in 50 ml of buffer containing 50
mM Tris, pH 7.5, 0.1 mM EGTA, 1 mM EDTA, 0.5 mM dithiothreitol, 0.5
mM phenylmethylsulfonyl fluoride, and 5 mg of protease inhibitors
leupeptin, aprotinin, and soybean trypsin inhibitor. Cells were dis-
rupted by freeze/thaw and extracts cleared by centrifugation at
10,000 3 g for 10 min. Peptide substrate (Peninsula Laboratories) was
as in Hubbard and Klee (28). CN activity was determined in the pres-
ence of 100 nM calmodulin and 5 mM 32P-labeled phosphopeptide in a
50-ml reaction mixture containing 20 mM Tris, pH 8.0, 100 mM NaCl, 6
mM MgCl2, 0.5 mM dithiothreitol, 0.1 mM CaCl2, and 20 ml of cell lysate.
Reactions were incubated at 30 °C for 15 min and stopped by the adition
of 5% trichloroacetic acid. Phosphate was isolated by Dowex AG 1-X8
chromatography and quantitated by scintillation counting. Alkaline
phosphatase activity was measured as previously reported (29). Lactate
dehydrogenase activity was measured using a spectrophotometric assay
(Boehringer Mannheim).
RESULTS AND DISCUSSION
CsA and PD 144795 Block p53 and NF-kB Binding to the
HIV-1 LTR—The HIV-1 LTR contains a binding site for a
proliferation-associated form of p53 (5). The p53 protein bound
to this site is in a proliferative or mutant-like unfolded state
based on recognition by specific monoclonal antibodies. This
DNA region mediates the induction of the HIV-1 LTR by tumor
necrosis factor a and by transforming mutant forms of p53.
Importantly, tumor necrosis factor a induces a physical inter-
action between p53 and Sp1 and this interaction is required for
the induction of HIV-1 LTR-mediated transcription by this
cytokine (6). We investigated whether or not p53/Sp1 binding to
the HIV-1 LTR is also induced by activation of the T cell
receptor. For that purpose, we performed EMSA using an oli-
gonucleotide probe (LTR B), CAGGGAGGCGTGGCCTGGGC-
GGGACTGGGG, that contains the composite p53 (underlined)
and Sp1 (italics) site in the HIV-1 LTR, and nuclear extracts
prepared from Jurkat T cells either unstimulated or stimulated
with PHA (Fig. 2A). Incubation with PHA induced the appear-
ance of two complexes, which we called PIC 1 and 2 (Fig. 2A).
Subsequent experiments indicated that maximal complex for-
mation by PHA was obtained at a 5-h incubation time (not
FIG. 2. Characterization of the PHA-induced nucleoprotein
complexes and inhibition of complex formation by cyclosporin
A and PD 144795. A, PHA induces the formation of specific nucleopro-
tein complexes on the HIV-1 LTR p53zSp1 composite site. Jurkat cells
cultured in a-minimal essential medium with 2% fetal calf serum and
penicillin/streptomycin, were resuspended in new media and incubated
for 4 h in the presence or absence of 5 mg/ml PHA. Cells were then
harvested and processed for the preparation of nuclear extracts. 2 mg of
nuclear extracts were assayed by EMSA using 0.2 ng of the LTR B probe
and 2 mg of poly(dIzdC) as indicated under “Experimental Procedures.”
B, identification of p53 and Sp1 in the PICs. Jurkat cells were incubated
with PHA as in A and nuclear extracts prepared. 2 mg of nuclear
extracts were incubated for 45 min at 4 °C with 0.2 mg of serum (NA),
monoclonal anti-p53 antibodies PAb 240 (240, conformational), 421
(421, C-terminal), 1620 (1620, conformational), 1801 (1801, N-termi-
nal); or polyclonal anti-Sp1 (Sp1), and then assayed by EMSA as in A.
C, CsA and PD 144795 inhibit the formation of PICs. Jurkat cells
cultured as in part A were preincubated for 30 min with 0.03% Me2SO
(NA), 0.5 mg/ml CsA, 100 ng/ml rapamycin (Rap), 3 mM PD 144795
(144795), or 100 mg/ml pentoxifilline, and then incubated for 4 h in the
presence of 5 mg/ml PHA. Equal volumes of Me2SO were added in each
condition. Nuclear extracts were prepared and assayed for binding to
the LTR B probe. D, binding of the nuclear extracts from the Me2SO-
(NA), CsA-, and PD 144795-treated cells to an Oct-1 probe. Conditions as
in C. E, effect of PD 144795 (144795) on the induction of p53/Sp1 binding
to the HIV-1 LTR by PHA and PMA. Jurkat cells cultivated as in A were
preincubated for 30 min in the presence or absence of 3 mM PD 144795,
and then incubated with 5 mg/ml PHA or 50 ng/ml PMA. Nuclear extracts
were prepared and assayed for nucleoprotein complex formation as in A.
FIG. 1. Chemical structure of compound PD 144795.
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shown). To confirm that these complexes contain p53 and Sp1,
extracts were incubated with antibodies against these proteins
prior to the mobility shift assay. Monoclonal anti-p53 PAb 421
and polyclonal anti-Sp1 demonstrated that p53 was present in
PIC 1 and 2 while Sp1 was detected only in PIC 1 (Fig. 2B). A
supershift was obtained with the anti-Sp1 antibody, whereas
disruption of Sp1/p53 binding to the LTR was observed with
the anti-p53 antibody PAb 421. We have previously shown that
PAb 421 specifically blocks p53 interaction with LTR B p53/Sp1
composite site (6).
Subsequent experiments were directed to determine if the
PHA-inducible binding of p53/Sp1 to the HIV-1 LTR is sensi-
tive to pharmacological modification. We performed EMSA
with nuclear extracts of Jurkat T cells incubated with PHA and
exposed to a series of pharmacological agents. Incubation of
Jurkat cells for 30 min with CsA or PD 144795 blocked the
induction of PICs by PHA, however, incubation with pentoxi-
fylline (data not shown), an NF-kB inhibitor (30), or the immu-
nosuppressant rapamycin (15) had no effect (Fig. 2C). Other
5-methoxybenzothiophene derivatives had minor or no effect on
PIC formation (not shown). Also, titration experiments indi-
cated that inhibition of the induction of the p53zSp1 complexes
was reached at 3 mM PD 144795 and 0.5 mg/ml CsA (not shown).
As a control, the nuclear extracts used in Fig. 2C were tested
for their ability to bind the HLA DRa octamer site using an
oligonucleotide sequence from this gene (46). No effect of CsA
or PD 144795 was detected on Oct-1 binding (Fig. 2D). The
identity of the Oct-1 complex was determined by supershift
with an anti-Oct-1 antibody (not shown). CsA and PD 144795
also inhibited the induction of p53zSp1 complexes in another T
cell line, CEM, when these cells were incubated in the presence
of the calcium ionophore A23187 (47) (not shown). Finally, the
effect of CsA and PD 144795 was specific for the TCR-depend-
ent signal and no effect of these compounds was detected when
Sp1zp53 complexes were induced by the incubation of the Jur-
kat cells with phorbol myristate acetate (PMA) (Fig. 2E).
Previous reports have shown that CsA inhibits the induction
by calcium-dependent signals of the DNA binding activity of
the transcription factors NF-AT and NF-kB (14, 22, 31–33). An
inhibition of NF-kB by PD 144795 could be critical for HIV-1
replication, as NF-kB is a major regulator of HIV-1 LTR-medi-
ated transcription (34, 35). We tested whether or not PD
144795 was able to block the induction by PHA of NF-kB
binding to its recognition sequence in the HIV-1 LTR. Nuclear
extracts from Jurkat cells, incubated as described above, were
assayed by EMSA using an oligonucleotide probe containing
the HIV-1 LTR NF-kB II site. A typical result of these experi-
ments is shown in Fig. 3A. Two specific complexes were iden-
tified using this probe. The faster mobility complex contained
NF-kB-p50/p50 homodimers whereas the slower mobility com-
plex was comprised of NF-kB p50/p65 heterodimers as indi-
cated by supershift with specific anti-NF-kB antibodies (Fig.
3B). Incubation of Jurkat cells with PHA increased p50/p65
binding while a minor effect was observed on p50/p50 ho-
modimers. PD 144795, as well as CsA, inhibited the PHA-
induced increase in the levels of p50/p65 heterodimers. No
effect of these drugs was observed on the binding of p50/p50
homodimers. The decrease in p50/p65 binding to a basal or
lower than basal level was observed in several experiments
(not shown). A certain variability in the level of basal p50/p65
binding was observed, probably resulting from activation of
NF-kB by growth factors present in the serum. CsA and PD
144795 also inhibited NF-kB p50/p65 binding in CEM lympho-
cytes when these cells were incubated in the presence of the
calcium ionophore A23187 (47) but not in the presence of PMA
(not shown). In summary, these results indicate that CsA and
PD 144795 specifically inhibit the activation by PHA of p53 and
NF-kB binding to the HIV-1 LTR. Intriguingly, these results
suggested that both compounds interfere with a common signal
transduction pathway that regulates transcription factors that
are critical for the expression of the HIV-1 promoter.
CsA and PD 144795 Inhibit the PHA-induced Transcrip-
FIG. 3. Effect of CsA and PD 144795 (Bz) on the induction of
NF-kB binding to the HIV-1 LTR by PHA. A, Jurkat cells were
cultured as in Fig. 1, preincubated for 30 min with CsA (0.5 mg/ml) or
PD 144795 (144795, 3 mM) as indicated, and then incubated for 5 h with
5 mg/ml PHA. Equal volumes of Me2SO were added in each condition.
Nuclear extracts and mobility shift assays were prepared as in A using
an oligonucleotide probe containing the 39 NF-kB-binding site. B, iden-
tification of NF-kB p50zp50 and p50zp65 DNA-binding complexes.
EMSA was performed using PHA-induced nuclear extracts and poly-
clonal NF-kB anti-p50 and anti-p65 antibodies.
FIG. 4. Inhibition by cyclosporin A and PD 144795 of the tran-
scriptional activity mediated by the HIV-1 LTR p53 and NF-kB
sites. A, CsA and PD 144795 (Bz) inhibit the induction by PHA of the
transcriptional activity mediated by the HIV-1 LTR. 3.5 3 107 Jurkat
cells were transfected by electroporation with 35 mg of the reporter
plasmid 2121,1232 HIV-1 LTR CAT. 8 h after transfection, cells were
aliquoted and incubated for 36 h with the additions indicated. 5 mg/ml
PHA, 50 ng/ml PMA, 1 mg/ml CsA, and 3 mM PD 144795 were used.
Equal amounts of Me2SO were used in all conditions. PD 144795 and
CsA were added 1 h before the addition of PHA or PMA. After the
incubation, the cells were collected by centrifugation and processed for
CAT activity as indicated under “Experimental Procedures.” CAT ac-
tivity was normalized to the basal activity of 2121,1232 HIV-1 LTR
CAT (approximately 5% acetylation). The figure shows the mean value
and S.D. of three independent experiments. B, CsA and PD 144795
inhibit the induction by PHA of the transcriptional activity mediated by
a minimal promoter construct containing the NF-kB and p53 sites.
Jurkat cells were transfected and incubated as in A but using the
reporter plasmid NF-kB/p53 E1BTATA CAT. CAT activity was normal-
ized to the basal activity of this vector (approximately 5% acetylation).
The figure represents three independent experiments. C, CsA and PD
144795 (Bz) did not affect the transcriptional activity mediated by p53
consensus sites. Normal human lung fibroblasts (WI-38 cells) were
transfected by lipofection with 5 mg of PG13. 8 h after transfection, the
cells were incubated in new media plus the additions indicated in the
figure. 5 mM phosphono-L-acetyl aspartate, 1 mg/ml CsA, and 3 mM PD
144795 were used. Cells were incubated for 3 days, then harvested and
CAT activity measured as indicated under “Experimental Procedures.”
CAT activity was normalized to the basal activity of PG13 (approxi-
mately 7% acetylation). The figure represents three independent
experiments.
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tional Activation of the HIV-1 LTR—To test the sensitivity of
the p53 and NF-kB-mediated transcriptional activities to CsA
and PD 144795 in vivo, transfection experiments were per-
formed in Jurkat T cells using the reporter plasmid 2121,1232
HIV-1 LTR CAT that contains the HIV-1 LTR kB II and p53
sites (5). After a 24-h incubation period, transfected cells were
aliquoted and incubated with PHA alone or in the presence of
CsA or PD 144795 for an additional 48 h. The results of these
experiments are shown in Fig. 4A. Incubation of the cells with
PHA and CsA or PD 144795 reduced CAT activity to approxi-
mately 50% of PHA alone. However, the PMA induction of the
transcriptional activity mediated by this promoter fragment
was not altered by the incubation with CsA or PD 144795.
Consistent with the idea of a common role for PD 144795 and
CsA, we observed that the activation of an interleukin-2 re-
porter plasmid by calcium-dependent signals was inhibited by
PD 144795 and CsA (not shown). These results parallel the
signal-specific inhibition by CsA and PD 144795 of p53 and
NF-kB binding in vitro.
To define the HIV-1 LTR DNA elements that are targeted by
PD 144795 and CsA, we tested the effect of these compounds on
the activity of NF-kB/p53-E1BTATA CAT, a minimal promoter-
FIG. 5. PD 144795 inhibits the phosphatase activity of calcineurin and activation by this enzyme of the transcriptional activity
mediated by the HIV-1 LTR. A, incubation of Jurkat cells with PD 144795 results in a dose-dependent inhibition of calcineurin. 107 Jurkat cells
were incubated for 2 h at 37 °C in media containing the concentrations of PD 144795 indicated in the figure. Cells were harvested by centrifugation
and extracts prepared and calcineurin (CN) and lactate dehydrogenase (LDH) activity reactions carried out as indicated under “Experimental
Procedures.” B, PD 144795 inhibits the phosphatase activity of calcineurin in lymphocyte extracts. Extracts from murine peripheral blood
lymphocytes were prepared and assayed for calcineurin activity as indicated under “Experimental Procedures.” The extracts were incubated 15 min
in the indicated concentration of PD 144795 or CsA before the addition of the substrate. Equal amounts of Me2SO were used per reaction. Released
phosphate was isolated and quantified by scintillation counting. The figure represents three independent experiments. B, inset, CsA and PD
144795 do not inhibit the activity of alkaline phosphatase. Cell extracts were treated as in B and assayed for alkaline phosphatase activity. C, PD
144795 antagonizes the activation by calcineurin of the transcriptional activity mediated by the HIV-1 LTR. Jurkat and WI-38 cells (fibroblasts)
were co-transfected with 5 mg of 2121,1232 HIV-1 LTR CAT and 1 mg of the expression vectors Sra (control, open bars) and Sra-DCAM (DCAM,
solid bars). 8 h after transfection cells were placed in new media with increased concentrations of PD 144795 and incubated for an aditional 48 h.
Equal amounts of Me2SO were used in all conditions. Transfections and CAT assays were carried out as described in the legend to Fig. 4. The
figures represent three independent experiments.
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reporter plasmid that contains a 32-base pair HIV-1 LTR frag-
ment comprising the NF-kB II and the proliferative p53 sites
subcloned upsteam of an heterologous TATA element. PD
144795 and CsA inhibited the PHA, but not the PMA induction
of NF-kB/p53-E1BTATA CAT activity in Jurkat T cells (Fig.
4B). PD 144795 and CsA did not affect the basal activity of the
minimal promoter element at the concentrations used in these
experiments (not shown). As a control we investigated the
effect of CsA and PD 144795 on the transcriptional activity
mediated by PG13, a CAT reporter plasmid containing 13 cop-
ies of an RGC consensus (antiproliferative) p53-binding site.
We transfected primary human fibroblasts with PG13 and
incubated these cells with the DNA synthesis inhibitor phos-
phono-L-acetyl aspartate because this compound induces the
transcriptional activity mediated by consensus p53 sites.2 Nei-
ther CsA nor PD 144795 altered the induction of PG13 activity
by phosphono-L-acetyl aspartate (Fig. 4C). No effect of PD
144795 or CsA was observed on the basal expression of PG13
(not shown). These experiments further demonstrated that PD
144795 and CsA target a common signal transduction pathway
that mediates the activation of the transcriptional activity of
NF-kB and proliferative p53 by ligands of the TCR.
PD 144795 Inhibits Calcineurin Activity—Since engagement
of the TCR activates HIV-1 LTR-mediated transcription
through a calcineurin-dependent pathway (12–14), and since
benzothiophene showed similar properties to CsA, we tested
the effect of PD 144795 on the activity of calcineurin, the
enzymatic activity that is targeted by CsA (16, 17). Incubation
of Jurkat cells with PD 144795 resulted in a dose-dependent
inhibition of the phosphatase activity of calcineurin (Fig. 5A).
PD 144795 did not decrease the activity of the enzyme lactate
dehydrogenase, indicating that this compound was not toxic to
the cells (Fig. 5A). PD 144795 and CsA also inhibited the
activity of calcineurin in Jurkat cell extracts (Fig. 5B). How-
ever, they did not affect the activity of the enzyme alkaline
phosphatase (Fig. 5B, inset), indicating that the effect of PD
144795 on calcineurin was specific.
Thus, our results demonstrate that PD 144795 targets the
same enzymatic activity as CsA, suggesting that inhibition of
calcineurin is a common mechanism of action of both drugs that
explains their similar effect on the transcriptional activity of
p53 and NF-kB. Current experiments in our laboratory indi-
cate that PD 144795 has additional effects on early events
associated with the activation of the TCR. For example, low
concentrations of PD 144795 induced a slow and steady in-
crease in the intracellular calcium levels in T lymphocytes and
inhibited the PHA-induced rise of intracellular calcium in
these cells.3
The effect of PD 144795 on the activity of calcineurin was
further investigated by experiments of overexpression of this
enzyme in vivo. It has been shown that overexpression of cal-
cineurin in Jurkat cells renders them more resistant to the
effects of CsA and FK 506 (48), another calcineurin-inhibitor
agent, and augments both NF-AT- and NF-interleukin-2A-de-
pendent transcription (18, 19). We co-transfected 2121,1232
HIV-1 LTR CAT with pSRa-DCAM, a pSRa expression vector
containing a constitutively active form of calcineurin, in Jurkat
cells and normal human fibroblasts. Calcineurin induced the
transcriptional activity of this HIV-1 LTR fragment in both cell
types (Fig. 5C). A higher induction was obtained in fibroblasts
(15-fold) than in Jurkat cells (6-fold). Incubation of the cells
with PD 144795 inhibited the effect of calcineurin in a dose-
response manner. Fibroblasts were more sensitive than Jurkat
cells to the inhibition by PD 144795. Half-maximal inhibition of
CAT activity by PD 144795 was reached at approximately at
0.2 mM in normal human fibroblasts and 1 mM in Jurkat cells. A
possible explanation for the cell-type difference in the response
to PD 144795 could be the existence of a mutant p53 allele in
the Jurkat cells (36). This mutant p53 protein may already
display in basal conditions the conformation necessary for the
interaction with HIV-1 LTR. Alternatively, Jurkat T cells may
carry other genetic alterations that result in a certain degree of
constitutive activation of NF-kB or p53. Interestingly, low con-
centrations of PD 144795 (0.3 mM) induced a moderate activa-
tion of 2121,1232 HIV-1 LTR CAT in both cell types. This
paradoxical effect may result from an indirect activation of
endogenous calcineurin by PD 144795 secondary to an increase
in the intracellular calcium levels induced by low concentra-
tions of the drug. This effect disappeared at higher concentra-
tions of PD 144795 as it was expected from its inhibitory effect
on calcineurin activity in vivo (Fig. 5A). The effect of the low
concentration of PD 144795 was not observed in cells trans-
fected with pSRa-DCAM. This calcineurin mutant is not af-
fected by alterations in the intracellular calcium levels (18).
Finally, since PD 144795 inhibits calcineurin and the tran-
scriptional activity mediated by NF-kB and p53, we investi-
gated whether or not calcineurin is involved in the regulation of
the transcriptional activity of NF-kB and p53. For that pur-
pose, we co-transfected CEM cells with a wild type HIV-1 LTR
CAT reporter or HIV-1 LTR CAT plasmids with mutated
NF-kB or p53 sites and the pSRa or pSRa-DCAM expression
vectors. The results of these experiments are shown in the Fig.
6. As expected, the activated form of calcineurin induced HIV-1
LTR CAT in this cell type. Importantly, mutagenesis of the
NF-kB or p53 sites completely abolished the induction of HIV-1
LTR activity by calcineurin, indicating that the transcriptional
activity of NF-kB and p53 can be modulated in a calcineurin-
dependent manner. Previous reports have indicated that cal-
cineurin inhibitors modulate NF-kB transcriptional activity
(14, 37–40). The regulation of p53 transcriptional activity by
calcineurin may have important implications for the growth
2 A. Gualberto, unpublished data. 3 R. Montaño and F. Sobrino, unpublished data.
FIG. 6. The NF-kB and p53 sites are required for the activation
of the HIV-1 LTR by calcineurin. CEM cells were co-transfected by
electroporation with 1 mg of the expression vectors Sra (empty vector,
open bars) or Sra-DCAM (DCAM, solid bars) and 5 mg of the CAT
reported vectors HIV-1 LTR (WT), HIV-1 LTR kBD (kBD), or p53D
(p53D) and incubated for 48 h. CAT assays were carried out as indicated
under “Experimental Procedures.” The figure represents three inde-
pendent experiments.
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regulatory functions of this protein. It has been shown that
proliferative forms of p53 may work as positive regulators of
cell growth (Refs. 41–43 and references therein). In addition,
recent data indicates that certain members of the NF-AT(Rel)
family of transcription factors can synergize with NF-kB and
Tat in the transcriptional activation of HIV-1 (44). Since
NF-AT activity is regulated by calcineurin (31, 40, 45), it is
possible that an NF-kB/NF-AT synergistic effect on HIV-1 LTR
transcription could be affected by PD 144795. In our experi-
mental conditions, NF-kB was solely accounted for by HIV-1 kB
site nucleoprotein complex formation (Fig. 3 and data not
shown). However, we cannot discard that a physical or func-
tional interaction between NF-kB and certain NF-AT family
members may take place in vivo and could be targetted by PD
144795.
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